CyberKnife Provides Long-term Disease Control for Prostate Cancer Patients


Photo of CyberKnife TechnologyJefferson now offers treatment with the CyberKnife® System, a noninvasive alternative to surgery for treating cancerous and noncancerous tumors, which has been shown to provide excellent long-term results for patients with low-and intermediate-risk prostate cancer.

According to a recent national 17-center study, after 10 years 98.4 percent of the 230 men monitored with low-risk prostate cancer who were treated with the CyberKnife System had local disease control, and 93.7 percent of patients were free of disease.

“Outcomes from this long-term, prospective study reinforce that CyberKnife prostate stereotactic body radiation therapy (SBRT) is highly effective, with typically minimal side effects and impact on quality of life during and after treatment,” said Donald B. Fuller, MD, at Genesis Healthcare Partners in San Diego, California, and lead investigator of the study. “It is important to note that nearly 90 percent of patients in the study were treated at community facilities across the United States, which may provide reassurance for men with localized prostate cancer that the results are achievable in their community setting.”

In addition, the study is the first to report on the efficacy and toxicity of SBRT in the treatment of low-risk prostate cancer following 10 years of treatment. The results were positive both in terms of disease control and tolerability, and were superior to long-term conventional intensity-modulated radiation therapy, based on results from previous studies.

The CyberKnife System delivers SBRT, a precise, high dose of radiation with the assistance of real-time image guidance. Cyberknife is the only system available to track prostate motion and automatically adjust the radiation beam during treatment.  Most patients prefer to receive only 5 SBRT treatments compared to conventional radiation therapy, which can typically take 30 or more treatments to complete.

Cyberknife has become increasingly popular among prostate cancer patients with low or intermediate risk due to its convenience and minimal disruption to patients’ daily lives. Cyberknife has also proven effective for other parts of the body including brain, spine and lung.

The CyberKnife treatment facility is located at the Rothman Orthopaedic Specialty Hospital in Bensalem, Pa. For more information call 215-244 7407 or visit

For full details of this study including the Accuray press release, visit: